These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31371039)

  • 21. Adding or switching antipsychotic medications in treatment-refractory schizophrenia.
    Kreyenbuhl J; Marcus SC; West JC; Wilk J; Olfson M
    Psychiatr Serv; 2007 Jul; 58(7):983-90. PubMed ID: 17602016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?
    Correll CU; Lauriello J
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia.
    Heres S; Reichhart T; Hamann J; Mendel R; Leucht S; Kissling W
    Eur Psychiatry; 2011; 26(5):297-301. PubMed ID: 20570493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers.
    Greene M; Burudpakdee C; Seetasith A; Behling M; Krasa H
    Curr Med Res Opin; 2019 Jan; 35(1):97-103. PubMed ID: 30322282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delaying time to relapse in schizophrenia. The role of long-acting injectable antipsychotics.
    Muller R
    Manag Care; 2014 Apr; 23(4 Suppl 1):2-3. PubMed ID: 25029779
    [No Abstract]   [Full Text] [Related]  

  • 26. Sharing decisions in consultations involving anti-psychotic medication: a qualitative study of psychiatrists' experiences.
    Seale C; Chaplin R; Lelliott P; Quirk A
    Soc Sci Med; 2006 Jun; 62(11):2861-73. PubMed ID: 16343722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.
    Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):14S-22S. PubMed ID: 23945063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a comprehensive information and assistance program for patients with schizophrenia treated with long-acting injectable antipsychotics.
    Benson CJ; Joshi K; Lapane KL; Fastenau J
    Curr Med Res Opin; 2015; 31(7):1437-48. PubMed ID: 25978698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
    Agid O; Foussias G; Remington G
    Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving Long-Term Outcomes in Patients With Schizophrenia: What Is the Evidence for Long-Acting Injectable Antipsychotics?
    Perkins DO
    J Clin Psychiatry; 2017; 78(9):e1431. PubMed ID: 29345879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics.
    Heres S; Lambert M; Vauth R
    Eur Psychiatry; 2014 Nov; 29 Suppl 2():1409-13. PubMed ID: 25455704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of long acting injectable atypical antipsychotics: a review.
    De Berardis D; Marini S; Carano A; Lang AP; Cavuto M; Piersanti M; Fornaro M; Perna G; Valchera A; Mazza M; Iasevoli F; Martinotti G; Di Giannantonio M
    Curr Clin Pharmacol; 2013 Aug; 8(3):256-64. PubMed ID: 23343445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychiatrist and patient responses to suspected medication nonadherence in schizophrenia spectrum disorders.
    Hamann J; Lipp ML; Christ-Zapp S; Spellmann I; Kissling W
    Psychiatr Serv; 2014 Jul; 65(7):881-7. PubMed ID: 24686753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychiatrists between personal freedom to prefer antipsychotic in treatment of schizophrenic patients and algorithms and guidelines.
    Loga S; Loga-Zec S
    Psychiatr Danub; 2010 Jun; 22(2):343-5. PubMed ID: 20562778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists.
    Correll CU; Brevig T; Brain C
    BMC Psychiatry; 2019 Nov; 19(1):362. PubMed ID: 31727015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
    Schanda H; Stompe T
    Neuropsychiatr; 2010; 24(1):14-26. PubMed ID: 20146916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.
    Apiquian R; Fresán A; de la Fuente-Sandoval C; Ulloa RE; Nicolini H
    BMC Psychiatry; 2004 Apr; 4():12. PubMed ID: 15109398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment.
    Markowitz MA; Levitan BS; Mohamed AF; Johnson FR; Bridges JF; Alphs L; Citrome L
    Psychiatr Serv; 2014 Sep; 65(9):1133-9. PubMed ID: 24828964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Family contact and the management of medication non-adherence in schizophrenia.
    Wilk JE; West JC; Marcus SC; Countis L; Regier DA; Olfson M
    Community Ment Health J; 2008 Oct; 44(5):377-80. PubMed ID: 18465228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.